Clinical Trial Update: Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) [Phase 3]

View source ↗

Summary

Open-label, long-term safety study of secukinumab in polymyalgia rheumatica is active/not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polymyalgia Rheumatica

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Polymyalgia Rheumatica | Phase 3 | Status: ACTIVE_NOT_RECRUITING